title: CD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinoma.
abstract: The inhibitory CD200:CD200 receptor axis is essential in preventing inflammatory responses during early microbial infection. It was reported in several tumor models that CD200 expression is closely associated to tumor progression and the blockade of this pathway may restore anti-tumor responses. Our study for the first time investigates the role of CD200:CD200R axis in relation to tumor progression and prognosis of human hepatocellular carcinoma. CD200 and CD200R protein expressions were evaluated by immunostaining on liver tissue specimens and we found higher expressions of CD200 and CD200R in HCC patients comparing to healthy controls. CD200 expresses in peritumoral, peritumoral stroma and intratumoral regions of HCC while CD200R predominantly expresses in peritumoral stroma. Furthermore, protein intensity of CD200R is positively associated to the diameter of tumor and alpha-fetoprotein level, in addition, patients with higher pathological grade and absence of tumor capsule exhibit higher CD200R expression. CD200R predominantly expresses on infiltrating macrophages and may associate with liver injury. Moreover, both overall and recurrence-free survival rates are significantly lower in patients with high CD200R expression comparing to those with low CD200R expression. Our findings suggest a promising role of CD200R as a prognostic marker in predicting elevated recurrence and reduced survival, and a potential therapeutic target in treating hepatocellular carcinoma.
authors: Institute of Immunology and The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui, China.
authors: Haoyu
authors: H
authors: Sun
authors: Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China.
authors: Jing
authors: J
authors: Xu
authors: Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, China.
authors: Mei
authors: M
authors: Huang
authors: Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, China.
authors: Qiang
authors: Q
authors: Huang
authors: Institute of Immunology and The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui, China.
authors: Rui
authors: R
authors: Sun
authors: Institute of Immunology and The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui, China. Electronic address: xiaow@ustc.edu.cn.
authors: Weihua
authors: W
authors: Xiao
authors: Institute of Immunology and The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui, China. Electronic address: charless@ustc.edu.cn.
authors: Cheng
authors: C
authors: Sun
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000954:Antigens, Surface / Q000378:metabolism*; D014408:Biomarkers, Tumor; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000276:immunology* / Q000378:metabolism* / Q000401:mortality; D018450:Disease Progression; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000175:diagnosis / Q000276:immunology* / Q000378:metabolism* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D064446:Orexin Receptors; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000378:metabolism*; D012008:Recurrence
chemical_list: D000954:Antigens, Surface; D014408:Biomarkers, Tumor; C477337:CD200R1 protein, human; D064446:Orexin Receptors; D011956:Receptors, Cell Surface
keywords: CD200 receptor; Co-inhibitory receptor; Hepatocellular carcinoma; Immunotherapy; Prognosis